Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lianhua Qingwen
- Development stage
- Phase 4
- Lead developer
- Yiling Pharmaceutical
- Administration
- Oral
01
Overview
Lianhua Qingwen is a widely used Traditional Chinese Medicine (TCM) formulation developed by Shijiazhuang Yiling Pharmaceutical. Originally created during the 2003 SARS outbreak, it has since been utilized for various viral respiratory infections, including influenza and COVID-19. The formulation is composed of 13 herbal ingredients, including *Lonicera japonica* (honeysuckle) and *Forsythia suspensa*. Its therapeutic effects are attributed to a multi-targeted mechanism that includes anti-viral activity (inhibiting viral entry and replication), anti-inflammatory action (suppressing pro-inflammatory cytokines like IL-6 and TNF-alpha), and immunomodulatory effects. It is primarily indicated for the treatment of fever, cough, and fatigue associated with viral infections such as the common cold, influenza, and COVID-19. In China, it is regulated as a pharmaceutical product and is available in both capsule and granule forms.
- Brand names
- Lianhua Qingwen
- Other names
- Lianhua Qingwen capsulesLianhua Qingwen granulesLianhua Qingwen JiaonangLianhua Qingwen Keli
02
Targets
IL-6 (Interleukin 6)Mpro (3C-like proteinase of SARS-CoV-2)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Lianhua Qingwen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lianhua Qingwen.